No Detail Found!

Enzalutamide Treatment in Metastatic Castration-resistant Prostate Cancer: Before and after Docetaxel

Author(s)
Irem Bilgetekin Department of Medical Oncology, Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital,Ankara,Turkey
Fatma Bugdayci Basal Department of Medical Oncology, Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital,Ankara,Turkey
Havva Yesil Cinkir Department of Medical Oncology, Gaziantep University Medical Faculty Hospital,Gaziantep,Turkey
Ece Esin Department of Medical Oncology, Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital,Ankara,Turkey
Berna Oksuzoglu Department of Medical Oncology, Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital,Ankara,Turkey
Umut Demirci Department of Medical Oncology, Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital,Ankara,Turkey
Abstract
Objective: To evaluate the e cacy and safety of enzalutamide in metastatic castration-resistant prostate cancer (mCRPC) in docetaxel-naive and docetaxel-pretreated patients. Study Design: Observational study. Place and Duration of Study: HSU Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Department of Medical Oncology, Ankara, Turkey, from March 2017 to July 2019. Methodology: A total of 67 patients with mCRPC were retrospectively evaluated. Castration-naive patients and non-metastatic patients were excluded from the study. Comorbid diseases, ECOG performance status, PSA response, and the radiological response of the patients were recorded. Kaplan-Meier method was used for survival analysis, and a Cox regression model was formed. Results: The overall survival (OS) was signi cantly longer in patients with eastern cooperative oncology group performance status (ECOG PS) 0 (26.0 vs. 14.0 months, p=0.031), PSA response (26.0 vs. 7.0 months, p=0.002), radiological response (26.0 vs. 10.0 months, p=0.006) and duration of enzalutamide e9 months (26.0 vs. 7.0 months, p<0.001) compared to ECOG PS 1. According to Cox regression analysis, patients with PSA response had 0.35 fold (CI.95% 0.13-0.94) reduced the risk of death and 0.36-fold (CI.95%0.16-0.85) reduced the risk of progression compared to those without PSA response. Moreover, longer enzalutamide treatment (e9 months) was noted to decrease the risk of death. Conclusion: PSA response, radiological response and duration of enzalutamide treatment may predict the improvement of survival in patients with mCRPC treated with enzalutamide.
Publication Details
Page(s) 815-821
DOI DOI not available
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 30, Issue: 8, Year: 2020

Request the full text from PASTIC

Keywords
overall survival, Castration-resistant prostate cancer, Docetaxel, Progression-free survival, Enzalutamide
0

Citations

0

Downloads

88

Views